Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry

Critical Reviews in Toxicology

Volumn 32, Issue 5, 2002, Pages 329-389

  Clewell, Harvey J ^a   Teeguarden, Justin ^a   McDonald, Tracy ^a   Sarangapani, Ramesh ^a   Lawrence, Greg ^a   Covington, Tammie ^a   Gentry, Robinan ^a   Shipp, Annette ^a  

^a ICF Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE; SULFOTRANSFERASE;

ABSORPTION; AGE; AIRWAY; BODY WEIGHT; DOSIMETRY; DRUG ELIMINATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENDER; GLUCURONIDATION; HUMAN; HYDROLYSIS; INDIVIDUALIZATION; KIDNEY CLEARANCE; NONHUMAN; OXIDATION; REDUCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TISSUE DISTRIBUTION; TOXICOKINETICS;

EID: 0036398887     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/20024091064264     Document Type: Review

References (145)

1. ICRP, Report of the Task Group on Reference Man. International Commission on Radiological Protection, New York, 1972.
2. Mayersohn, M., Pharmacokinetics in the elderly. Environmental Health Perspectives, 102(Suppl 11), 119-124, 1994.
3. Braunlich, H., Kidney Development: Drug Elimination Mechanisms, in Drug Disposition During Development, Morselli, P., Ed. Spectrum Publications Inc., New York, 89-101, 1977.
4. Ogiu, N., et al., A statistical analysis of the internal organ weights of normal Japanese people. Health Phys, 72(3), 368-83, 1997.
5. Crystal, R.G., et al., Eds., The Lung : Scientific Foundations. Vol. 2. Raven Press: New York, 1991.
6. Plunkett, L.M., Turnbull, D., and Rodricks, J.V., Differences Between Adults and Children Affecting Exposure Assessment, in Similarities and Differences Between Children and Adults: Implications for Risk Assessment, Guzelian, P., Henry, C., and Olin, S., Eds., ILSI Press, Washington, DC, 79-94, 1992.
7. Bender, A.D., Effect of age on intestinal absorption: implications for drug absorption in the elderly. Journal of the American Geriatric Society, 16(12), 1331-1339, 1968.
8. Eddington, N.D., Pharmacokinetics, in Handbook of Pharmacology and Aging, Roberts, J., Snyder, D.L., and Friedman, E., Eds., CRC Press, Boca Raton, 1-22, 1996.
9. Klaassen, C.D., Distribution, Excretion, and Absorption of Toxicants, in Toxicology: The Basic Science of Poisons, Klaassen, C.D., Amdur, M.O., and Doull, J., Eds., Macmillan Publishing, New York, 33-63, 1980.
10. Beierle, I., Meibohm, B., and Derendorf, H., Gender differences in pharmacokinetics and pharmacodynamics. International Journal of Clinical Pharmacology and Therapeutics, 37(11), 529-47, 1999.
11. Bearer, C.F., How are children different from adults? Environmental Health Perspectives, 103(Suppl 6), 7-12, 1995.
12. Cunico, R.L., et al., Skin barrier properties in the newborn. Biol Neonate, 32(177-182, 1977.
13. Milsap, R.L. and Jusko, W.J., Pharmacokinetics in the infant. Environmental Health Perspectives, 102(Suppl 11), 107-110, 1994.
14. Roskos, K.V., Maibach, H.I., and Guy, R.H., The effect of aging on percutaneous absorption in man. Journal of Pharmacokinetics and Biopharmaceutics, 17(6), 617-630, 1989.
15. Reid, L.M., The pulmonary circulation: remodeling in growth and disease. The 1978 J. Burns Amberson lecture. Am Rev Respir Dis, 119(4), 531-46, 1979.
16. Dunnill, M.S., The problem of lung growth [editorial]. Thorax, 37(8), 561-3, 1982.
17. Musante, CJ. and Martonen, T.B., Computer simulations of particle deposition in the developing human lung. Journal of the Air and Waste Management Association, 50(8), 1426-1432, 2000.
18. Snodgrass, W., Physiological and Biochemical Differences Between Children and Adults as Determinants of Toxic Response to Environmental Pollutants., in Similarities and Differences Between Children and Adults: Implications for Risk Assessment, Guzelian, P., Henry, C., and Olin, S., Eds., ILSI Press, Washington, DC, 35-42, 1992.
19. Gillooly, M. and Lamb, D., Airspace size in lungs of lifelong non-smokers: effect of age and sex. Thorax, 48(1), 39-43, 1993.
20. Mauderly, J.L., Effect of age on pulmonary structure and function of immature and adult animals and man. Fed Proc, 38(2), 173-7, 1979.
21. Cook, D.R., Paediatric anaesthesia: Pharmacological considerations. Drugs, 12(3), 212-221, 1976.
22. Roth, W.L., Freeman, R.A., and Wilson, A.G., A physiologically based model for gastrointestinal absorption and excretion of chemicals carried by lipids. Risk Analysis, 13(5), 531-543, 1993.
23. Vost, A. and Maclean, N., Hydrocarbon transport in chylomicrons and high-density lipoproteins in rat. Lipids, 19(6), 423-435, 1984.
24. Stewart, C.F. and Hampton, E.M., Effect of maturation on drug disposition in pediatric patients. Clinical Pharmacology, 6(7), 548-564, 1987.
25. Hattis, D., et al., Development of a Comparative Child/Adult Pharmacokinetic Database Based Upon the Therapeutic Drug Literature. Clark University and the Connecticut Department of Public Health, 2000.
26. Morselli, P.L., Franco-Morselli, R., and Bossi, L., Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clinical Pharmacokinetics, 5(6), 485-527, 1980.
27. Burin, G.J. and Saunders, D.R., Addressing human variability in risk assessment - the robustness of the intraspecies uncertainty factor. Regulatory Toxicology and Pharmacology, 30(3), 209-216, 1999.
28. Parkinson, A., Biotransformation of Xenobiotics, in Casarett and Doull's Toxicology, The Basic Science of Poisons, Klaasen, C., Ed. McGraw-Hill, New York, 113-186, 1996.
29. Maurel, P., The CYP3 family, in Cytochromes P450 Metabolic and Toxicological Aspects, C, I., Ed. CRC Press, Boca Raton, FL, 241-270, 1996.
30. de Wildt, S.N., et al., Cytochrome P450 3A: ontogeny and drug disposition. Clinical Pharmacokinetics, 37(6), 485-505, 1999.
31. Guengerich, F.P. and Shimada, T., Oxidation of Toxic and Carcinogenic Chemicals by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 4(4), 391-407, 1991.
32. Glue, P. and Clement, R.P., Cytochrome P450 enzymes and drug metabolism - basic concepts and methods of assessment. Cellular and Molecular Neurobiology, 19(3), 309-323, 1999.
33. Kovarik, J.M. and Koelle, E.U., Cyclosporin pharmacokinetics in the elderly. Drugs and Aging, 15(3), 197-205, 1999.
34. Calabrese, E., Xenobiotic Metabolism, in Age and Susceptibility to Toxic Substances, Calabrese, E., Ed. John Wiley, New York, 33-78, 1986.
35. Kawajiri, K., Hayashi, S.I., The CYP1 family, in Cytochromes P450 Metabolic and Toxicological Aspects, C, I., Ed. CRC Press, Boca Raton, FL, 77-97, 1996.
36. Shimada, T., et al., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270(1), 414-423, 1994.
37. Tanaka, E., Gender-related differences in pharmacokinetics and their clinical significance. Journal of Clinical Pharmacology and Therapeutics, 24(5), 339-346, 1999.
38. Sonawane, B.R. and Yaffe, S.J., Clinical implications of hepatic immaturity: bilirubin glucuronidation and induction by phenobarbital, in Drug Metabolism in the Immature Human, Soyka, L.F., Redmond, G.P., Ed. Raven Press, New York, 119-128, 1981.
39. Pacifici, G.M., et al., Tissue and species differences in enzymes of epoxide metabolism. Xenobiotica, 11(2), 73-79, 1981.
40. Mendrala, A.L., et al., In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse, and human. Archives of Toxicology, 67(1), 18-27, 1993.
41. Rane, A., Pacifici, G.M., Formation and metabolism of toxic metabolites in the human fetus, in Drug Metabolism in the Immature Human, Soyka, L.F., Redmond, G.P., Ed. Raven Press, New York, 29-35, 1981.
42. Kauffman, R.E., Acute Acetaminophen Overdose: An Example of Reduced Toxicity Related to Developmental Differences in Drug Metabolism, in Similarities and Differences Between Children and Adults: Implications for Risk Assessment, Guzelian, P., Henry, C., and Olin, S., Eds., ILSI Press, Washington, DC, 97-103, 1992.
43. Klaassen, C.D. and Rozman, K., Absorption, distribution, and excretion of toxicants, in Casarett and Doull's Toxicology. The Basic Science of Poisons, Amdur, M.O., Doull, J., and Klaassen, C.D., Eds., Pergamon Press, New York, 50-87, 1991.
44. Rozman, K.K. and Klaassen, C.D., Absorption, distribution, and excreiton of toxicants, in Casarett and Doull's Toxicology. The Basic Science of Poisons, Klaassen, C.D., Amdur, M.O., and Doull, J., Eds., McGraw-Hill, New York, 91-112, 1996.
45. Fullmer, C.S., Intestinal interactions of lead and calcium. NeuroToxicology, 13(4), 799-807, 1992.
46. Ritschel, W.A., Ed. Gerontokinetics. Pharmacokinetics of Drugs in the Elderly. The Telford Press, Inc.: Caldwell, NJ, 1988.
47. Calabrese, E., Gastrointestinal/ Dermal/Pulmonary Absorption or Xenobiotics: Effect of Age., in Age and Susceptibility to Toxic Substances, Calabrese, E., Ed. John Wiley, New York, 5-24, 1986.
48. Widdicombe, J., Drug uptake from the airways and lungs. Indian Journal of Physiology and Pharmacology, 42(1), 3-14, 1998.
49. Johanson, G., Modeling of Respiratory Exchange of Polar Solvents. Annals of Occupational Hygiene, 35(3), 323-339, 1991.
50. Andersen, M.E., Saturable metabolism and its relation to toxicity. Critical Reviews in Toxicology, 9(105-150, 1981.
51. Andersen, M.E., A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. Toxicology and Applied Pharmacology, 60(509-526, 1981.
52. Guilmette, R., Wicks, J., and Wolff, R., Morphometry of human nasal airways in vivo using magnetic resonance imaging. J Aerosol Med, 2(365-377, 1989.
53. Sarangapani, R. and Wexler, A.S., Modeling particle deposition in extrathoracic airways. Aerosol. Sci. Technol., 32(72-89), 2000.
54. Schoenberg, J.B., Beck, G.J., and Bouhuys, A., Growth and decay of pulmonary function in healthy blacks and whites. Respir Physiol, 33(3), 367-93, 1978.
55. Quanjer, P.H., et al., Compilation of reference values for lung function measurements in children. Eur Respir J Suppl, 4(184S-261S, 1989.
56. Sherrill, D.L., Camilli, A., and Lebowitz, M.D., On the temporal relationships between lung function and somatic growth. Am Rev Respir Dis, 140(3), 638-44, 1989.
57. Hislop, A.A., et al., Postnatal growth and function of the pre-acinar airways. Thorax, 27(265-274, 1972.
58. Krumpe, P.E., et al., The aging respiratory system. Clin Geriatr Med, 1(1), 143-75, 1985.
59. Weibel, E.R., Morphometry of the Human Lung. Berlin, Springer, 151, 1963.
60. Thurlbeck, W.M., Postnatal human lung growth. Thorax, 37(8), 564-71, 1982.
61. Crapo, R.O., Pulmonary-function testing. N Engl J Med, 331(1), 25-30, 1994.
62. Gibson, G.J., et al., Sex and age differences in pulmonary mechanics in normal nonsmoking subjects. J Appl Physiol, 41(1), 20-5, 1976.
63. Leith, D.E. and Mead, J., Mechanisms determining residual volume of the lungs in normal subjects. J Appl Physiol, 23(2), 221-7, 1967.
64. Mellemgaard, K., The alveolar-arterial oxygen difference: its size and components in normal man. Acta Physiol Scand, 67(1), 10-20, 1966.
65. Hamer, N., Effect of membrane permeability on pulmonary as exchange efficiency. Clin. Sci., 23(85, 1962.
66. Krumholz, R.A., Pulmonary membrane diffusing capacity and pulmonary capillary blood volume: an appraisal of their clinical usefulness. Am Rev Respir Dis, 94(2), 195-200, 1966.
67. Verbeken, E.K., et al., Anatomy of membranous bronchioles in normal, senile and emphysematous human lungs. J Appl Physiol, 77(4), 1875-84, 1994.
68. Edge, J., Millard, F., and Reid, L., The radiographic appearance of the chest in persons of advanced age. Br. J. Radiol, 37(769-774, 1984.
69. Petrini, M.F., Phillips, M.S., and Walsh, D.A., Pulmonary tissue volume and blood flow as functions of body surface area and age. Lung, 166(1), 47-63, 1988.
70. Hofmann, W., Mathematical model for the postnatal growth of the human lung. Respir Physiol, 49(1), 115-29, 1982.
71. Overton, J.H. and Graham, R.C., Predictions of ozone absorption in human lungs from newborn to adult. Health Phys, 57 Suppl 1(4), 29-36, 1989.
72. Martonen, T.B., Graham, R.C., and Hofmann, W., Human subject age and activity level: factors addressed in a biomathematical deposition program for extrapolation modeling. Health Phys, 57 Suppl 1(8), 49-59, 1989.
73. Agnew, J.E., Bronchiolar aerosol deposition and clearance. Eur Respir J, 9(6), 1118-22, 1996.
74. Stanley, P.J., et al., Effect of betamethasone and betamethasone with neomycin nasal drops on human nasal mucociliary clearance and ciliary beat frequency. Thorax, 40(8), 607-12, 1985.
75. Leikauf, G.D., et al., Dose-dependent effects of submicrometer sulfuric acid aerosol on particle clearance from ciliated human lung airways. Am Ind Hyg Assoc J, 45(5), 285-92, 1984.
76. Davis, J. and Grant, L., The Sensitivity of Children to Lead, in Similarities and Differences Between Children and Adults: Implications for Risk Assessment, Guzelian, P., Henry, C., and Olin, S., Eds., ILSI Press, Washington, DC, 150-162, 1992.
77. Swift, D.L., Age-related scaling for aerosol and vapor deposition in the upper airways of humans. Health Phys, 57 Suppl 1(293-7, 1989.
78. Oldham, M.J., Mannix, R.C., and Phalen, R.F., Deposition of monodisperse particles in hollow models representing adult and child-size tracheobronchial airways. Health Phys, 72(6), 827-34, 1997.
79. EPA, Air Quality Criteria Document for Particulate Matter, 1996.
80. Bennett, W.D., Zeman, K.L., and Kim, C., Variability of fine particle deposition in healthy adults: effect of age and gender. Am J Respir Crit Care Med, 153(5), 1641-7, 1996.
81. Xu, G.B. and Yu, C.P., Effects of age on deposition of inhaled aerosols in the human lung. Aero Sci Tech, 5(359-357, 1986.
82. Phalen, R.F., et al., Tracheobronchial deposition predictions for infants, children and adolescents. Ann Occup Hyg, 32(Suppl), 11-21, 1988.
83. McCue, J.D., Antibiotic use in the elderly: issues and nonissues. Clinical Infectious Diseases, 28(4), 750-752, 1999.
84. Corley, R.A., Gordon, S.M., and Wallace, L.A., Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures. Toxicological Sciences, 53(1), 13-23, 2000.
85. Nomiyama, K. and Nomiyama, H., Metabolism of Trichloroethylene in Human. Sex Difference in Urinary Excretion of Trichloroacetic Acid and Trichloroethanol. Internationales Archiv Fur Arbeitsmedizin, 28(1), 37-48, 1971.
86. Pritchard, J.N., Jefferies, S.J., and Black, A., Sex differences in the regional deposition of inhaled particles in the 2.5-7.5 um size range. J Aero Sco, 17(385-389, 1986.
87. Kim, C.S. and Hu, S.C., Regional deposition of inhaled particles in human lungs: comparison between men and women. J Appl Physiol, 84(6), 1834-44, 1998.
88. Jaques, P.A. and Kim, C.S., Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol, 12(8), 715-31, 2000.
89. Crom, W.R., Pharmacokinetics in the child. Environmental Health Perspectives, 102(Suppl 11), 111-117, 1994.
90. Ulijaszek, S.J., Johnston, F.E., and Preece, M.A., Eds., Human Growth and Development. Cambridge University Press: New York. 497, 1998.
91. DeVane, C.L., Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cellular and Molecular Neurobiology, 19(4), 443-466, 1999.
92. Masseyeff, R., et al., Evolution of alpha-fetoprotein serum levels throughout life in humans and rats, and during pregnancy in the rat. Annals of the New York Academy of Sciences, 259(17-28, 1975.
93. Dunn, J., Transport of Estrogens in Human Plasma, in Catechol Estrogens, Merriam, G. and Lipsett, M., Eds., Raven Press, New York, 167-176, 1983.
94. Dunn, J., Computer Simulation of Steroid Transport in Human Plasma, in Computers in Endocrinology, Rodbard, D. and Forti, G., Eds., Raven Press, New York, 277-285, 1984.
95. Zubenko, G.S. and Sunderland, T., Geriatric psychopharmacology: why does age matter? Harvard Review of Psychiatry, 7(6), 311-333, 2000.
96. Schussler, G.C., The thyroxine-binding proteins [published erratum appears in Thyroid 2000 Apr; 10(4):372]. Thyroid, 10(2), 141-149, 2000.
97. Newcomer, M.E., Retinoid-binding proteins: structural determinants important for function. FASEB Journal, 9(2), 229-239, 1995.
98. Kurz, H., Mauser-Ganshorn, A., and Stickel, H.H., Differences in the binding of drugs to plasma proteins from newborn and adult man. I. European Journal of Clinical Pharmacology, 11(6), 463-467, 1977.
99. Grandison, M.K. and Boudinot, F.D., Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet, 38(3), 271-90, 2000.
100. Hay, W.W., Jr., et al., Eds., Current Pediatric Diagnosis and Treatment, 14th ed. Appleton & Lange: Stamford, CT, 1998.
101. Morselli, P.L., Ed. Drug Disposition During Development. Spectrum Publications, Inc.: New York, 1979.
102. Belgorosky, A. and Rivarola, M.A., Progressive decrease in serum sex hormone-binding globulin from infance to late prepuberty in boys. J Clin Endocrinol Metab, 63(2), 510-512, 1986.
103. Bedecarras, P., et al., Characterization of serum SHBG isoforms in prepubertal and pubertal girls. Clin Endocrinol, 49(5), 603-608, 1998.
104. Hakkinen, K. and Pakarinen, A., Serium hormones and strength development during strength training in middle-aged and elderly males and females. Acta Physiol Scand, 150(2), 211-219, 1994.
105. Kurz, H., Michels, H., and Stickel, H.H., Differences in the binding of drugs to plasma proteins from newborn and adult man. II. European Journal of Clinical Pharmacology, 11(6), 469-472, 1977.
106. Ritschel, W., et al., Pharmacokinetics of coumarin and its 7-hydroxymetabolites upon intravenous and peroral administration of coumarin in man. European Journal of Clinical Pharmacology, 12(6), 457-461, 1977.
107. Gilmore, D.A., et al., Age and gender influence the stereoselective pharmacokinetics of propranolol. Journal of Pharmacology and Experimental Therapeutics, 261(3), 1181-6, 1992.
108. Cogliano, J., Trichloroethylene health risk assessment: Using mechanistic information to improve dose-response assessment. The Toxicologist, 48(1-S), Abstr # 387, 1999.
109. Veering, B.T., et al., The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. British Journal of Clinical Pharmacology, 29(2), 201-206, 1990.
110. Piafsky, K.M., et al., Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alphal acid glycoprotein. New England Journal of Medicine, 299(26), 1435-1439, 1978.
111. Triggs, E. and Charles, B., Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly. Clinical Pharmacokinetics, 37(4), 331-341, 1999.
112. Wilson, K., Sex-related differences in drug disposition in man. Clin Pharmacokinet, 9(3), 189-202, 1984.
113. Klinger, W., Development of Drug Metabolizing Enzymes, in Drug Disposition During Development, PL, M., Ed. Spectrum Publications, Inc., New York, 71-87, 1977.
114. Birkett, D.J. and Grygiel, J.J., Age determinants of methylxanthine metabolism in man, in Drug Metabolism in the Immature Human, Soyka LF, R.G., Ed. Raven Press, New York, 229-239, 1981.
115. Cresteil, T., Onset of xenobiotic metabolism in children: toxicological implications. Food Additives and Contaminants, 15(Suppl), 45-51, 1998.
116. Lacroix, D., et al., Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occursimmediately after birth. Eur J Biochem, 247(2)(625-634, 1997.
117. Jacqz-Aigrain, E. and Cresteil, T., Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev Pharmacol Ther, 18(3-4)(161-168, 1992.
118. Treluyer, J., et al., Expression of CYP2D6 in developing human liver. Eur J Biochem, 202(2)(583-588, 1991.
119. Trelyuer, J., et al., Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in virtro correlation and inducibility. Pharmacogenetics, 7(441-452, 1997.
120. Sonnier, M. and Cresteil, T., Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem, 251(3)(893-898, 1998.
121. Vieira, I., Sonnier, M., and Cresteil, T., Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem, 238(476-483, 1996.
122. Sipes, I.G., Gandolfi, A.J., Biotransformation of toxicants, in Casarett and Doull's Toxicology, C.D. Klaassen, J.O.A., J. Doull, Ed. Macmillan Publishing Company, New York, 64-98, 1986.
123. Landi, M.T., et al., Chapter 16. Human cytochrome P4501A2. IARC Science Publications, 148(173-195, 1999.
124. Ryan, D.E. and Levin, W., Age- and gender-related expression of rat liver cytochrome P450, in Handbook of Experimental Pharmacology, J. Schenkman, H.G., Ed. Springer-Verlag, Yew York, 461-476, 1993.
125. Richardson, T.H., Johnson, E.F., The CYP2C subfamily, in Cytochromes P450 Metabolic and Toxicological Aspects, C, I., Ed. CRC Press, Boca Raton, FL, 161-181, 1996.
126. Vahter, M., Methylation of inorganic arsenic in different mammalian species and population groups. Science in Progress, 82(Pt 1), 69-88, 1999.
127. Dutton, G.J., Glucuronidation of Drugs and Other Compounds. Boca Raton, FL, CRC Press, 1980.
128. Pastino, G.M., Yap, W.Y., and Carroquino, M., Human variability and susceptibility to trichloroethylene. Environmental Health Perspectives, 108(Suppl 2), 201-214, 2000.
129. John, E.G. and Guignard, J.-P., Development of Renal Excretion of Drugs During Ontogeny, in Fetal and Neonatal Physiology, Polin, R. and Fox, W., Eds., W.B. Saunders Company, Philadelphia, 188-193, 1998.
130. Podrazik, P.M. and Schwartz, J.B., Cardiovascular pharmacology of aging. Cardiology Clinics, 17(1), 17-34, 1999.
131. Stalam, M. and Kaye, D., Antibiotic agents in the elderly. Infectious Disease Clinics of North America, 14(2), 357-369, 2000.
132. Bokenkamp, A., et al., Cystatin C - a new marker of glomerular filtration rate in children independent of age and height. Pediatrics, 101(5), 875-881, 1998.
133. Fletcher, C.V., Acosta, E.P., and Strykowski, J.M., Gender differences in human pharmacokinetics and pharmacodynamics. Journal of Adolescent Health, 15(8), 619-629, 1994.
134. Atherton, D.P. and Hunter, J.M., Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clinical Pharmacokinetics, 36(3), 169-189, 1999.
135. Tod, M., Padoin, C., and Petitjean, O., Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clinical Pharmacokinetics, 38(3), 205-223, 2000.
136. Sproule, B.A., Hardy, B.G., and Shulman, K.I., Differential pharmacokinetics of lithium in elderly patients. Drugs and Aging, 16(3), 165-177, 2000.
137. Giroux, D., Lapointe, G., and Baril, M., Toxicological index and the presence in the workplace of chemical hazards for workers who breast-feed infants. Am Ind Hyg Assoc J, 53(7), 471-474, 1992.
138. Byczkowski, J.Z., Geahart, J.M., and Fisher, J.W., "Occupational" exposure of infants to toxic chemicals via breast milk. Nutrition, 10(1), 43-48, 1994.
139. Shelley, M.L., Andersen, M.E., and Fisher, J.W., A risk assessment approach for nursing infants exposed to volatile organics through the mother's occupational inhalation exposure. Appl Ind Hyg, 4(1), 21-26, 1989.
140. Byczkowski, J.Z. and Fisher, J.W., Tetrachloroethylene exposure assessment of breast-fed infants. undated.
141. Byczkowski, J., Lactional Transfer of Chemicals. Seminar presentation. February 5, 1992. 1992.
142. Miller, R.K., Koszalka, T.R., and Brent, R.L., The transport of molecules across placental membranes, in The Cell Surface in animal Embryogenesis and Development, Poste, G. and Nicolson, G.L., Eds., Elsevier, New York, 145-223, 1976.
143. Guyton, A.C. and Hall, J.E., Textbook of Medical Physiology. 9th ed. Philadelphia, W.B. Saunders Company, 1996.
144. Widdowson, E.M., Changes in Body Proportions and Compositions During Growth, in Scientific Foundations of Paediatrics, Davis, J. and Dobbing, J., Eds., W. Heinemann Medical Books Ltd;, London, 153-163, 1974.
145. Pikkarainen, P.H. and Raiha, N.C., Development of alcohol dehydrogenase activity in the human liver. Pediatric Research, 1(3), 165-168, 1967.